My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astria Therapeutics, Inc. - Common Stock (NQ:ATXS)

11.92 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13
Open 11.92
Bid (Size) 11.74 (10)
Ask (Size) 12.00 (1)
Prev. Close 11.92
Today's Range 11.92 - 11.92
52wk Range 3.555 - 12.52
Shares Outstanding 56,434,219
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS and RYN on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play
Via Stocktwits

Performance

YTD
+32.9%
+32.9%
1 Month
+61.7%
+61.7%
3 Month
+88.3%
+88.3%
6 Month
+199.5%
+199.5%
1 Year
+3.7%
+3.7%

More News

Read More
Dow Jumps Over 300 Points; Citigroup Posts Upbeat Earnings
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
BioCryst To Acquire Astria Therapeutics In $700M Deal
Via Stocktwits
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
Via Benzinga
Which stocks are gapping on Tuesday?
Via Chartmill
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Which stocks are moving before the opening bell on Tuesday?
Via Chartmill
ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Inc (NASDAQ:ATXS) Reports Narrower-Than-Expected Q2 2025 Loss and Strong Cash Runway
Via Chartmill
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit
From Astria Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Astria Therapeutics, Inc. - Common Stock publicly traded?
Yes, Astria Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Astria Therapeutics, Inc. - Common Stock trade on?
Astria Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Astria Therapeutics, Inc. - Common Stock?
The ticker symbol for Astria Therapeutics, Inc. - Common Stock is ATXS on the Nasdaq Stock Market
What is the current price of Astria Therapeutics, Inc. - Common Stock?
The current price of Astria Therapeutics, Inc. - Common Stock is 11.92
When was Astria Therapeutics, Inc. - Common Stock last traded?
The last trade of Astria Therapeutics, Inc. - Common Stock was at 10/15/25 04:15 PM ET
What is the market capitalization of Astria Therapeutics, Inc. - Common Stock?
The market capitalization of Astria Therapeutics, Inc. - Common Stock is 672.70M
How many shares of Astria Therapeutics, Inc. - Common Stock are outstanding?
Astria Therapeutics, Inc. - Common Stock has 673M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.